Galmed Pharmaceuticals (GLMD) EPS (Weighted Average and Diluted) (2013 - 2020)

Galmed Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at $0.32 for Q1 2020.

• In Q1 2020, EPS (Weighted Average and Diluted) rose 49.07% year-over-year to $0.32; the TTM figure through Dec 2020 stood at $0.32 (down 17.85% YoY), while the FY2025 annual figure was $2.39, down 70.42% from the prior year.
• EPS (Weighted Average and Diluted) was $0.32 for Q1 2020 at Galmed Pharmaceuticals, down from $0.39 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.42 in Q4 2016 to a low of $0.04 in Q3 2018.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.27 across 5 years, with a median of $0.25 in 2017.
• The sharpest annual moves came in 2018 and 2019: EPS (Weighted Average and Diluted) slumped 82.96% in 2018, then soared 453.48% in 2019.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.42 in 2016, then tumbled by 31.22% to $0.29 in 2017, then dropped by 29.98% to $0.2 in 2018, then jumped by 92.06% to $0.39 in 2019, then slipped by 17.34% to $0.32 in 2020.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.32 (Q1 2020), $0.39 (Q4 2019), and $0.21 (Q3 2019), per Business Quant data.